UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for hepatitis B and hepatitis C in the United Kingdom. Explore treatment pathways including direct-acting antivirals and functional cure research.
Hepatitis B and C affect ~270,000 and ~143,000 people respectively in the UK. Both can cause chronic liver infection leading to cirrhosis and liver cancer. Hepatitis C can now be cured in >95% of patients with direct-acting antivirals. Hepatitis B can be controlled but a functional cure (complete elimination) remains the goal of current research.
Direct-acting antivirals (DAAs) have revolutionised hepatitis C treatment: 8-12 weeks of oral tablets cures >95% of patients with minimal side effects. Regimens include sofosbuvir/velpatasvir (Epclusa), glecaprevir/pibrentasvir (Mavyret), and sofosbuvir/ledipasvir (Harvoni). NICE recommends treatment for all HCV patients regardless of liver disease stage. The NHS aims to eliminate hepatitis C by 2025.
Current treatment: pegylated interferon (finite course) or nucleos(t)ide analogues (entecavir, tenofovir) long-term. These suppress the virus but rarely achieve a functional cure (HBsAg loss). Research is focused on combination approaches to achieve functional cure: capsid inhibitors, siRNA therapies (bepirovirsen), therapeutic vaccines, and entry inhibitors. NICE recommends treatment for active HBV with elevated ALT or significant fibrosis.
Active UK hepatitis trials include: HBV functional cure combinations (siRNA + capsid inhibitor + immunotherapy), HCV elimination strategies (find-and-treat programmes for underserved populations), liver fibrosis reversal, therapeutic vaccines for HBV, and point-of-care diagnostics. The NHS England HCV elimination programme is the first of its kind globally.
Free AI-powered matching - no signup required
Search hepatitis B Trials →